BioCryst Pharma (NASDAQ:BCRX) Azioni

BIOCRYST PHARMACEUTICALS INC

BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday.
The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&amp;P 500 also fell, dropping, 0.26% to 5,671.90.
Check This Out: <a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a>
Leading and Lagging Sectors Industrials shares rose by 0.2% on Monday.
In trading on Monday, energy stocks dipped by 1.9%.
Top Headline
The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hyperscale Data, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) shares shot up 202% to $4.14 after the company issued first-quarter and FY25 sales guidance.</li>
<li>Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) got a boost, surging 25% to $61.70 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares were also up, gaining 12% to $10.01 after the company reported a first-quarter sales beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) shares dropped 29% to $11.94 after the company reported a first-quarter adjusted EPS miss and cut its FY25 adjusted EPS guidance.</li>
<li>Shares of PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) were down 18% to $40.87. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington&#8217;s disease patients.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) was down, falling 16% to $36.53 after the company reported worse-than-expected first-quarter EPS results.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $57.00 while gold traded up 2.5% at $3,323.40.
Silver traded up 0.6% to $32.455 on Monday, while copper rose 0.3% to $4.6875.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.06%, while Spain's IBEX 35 Index gained 0.40%. Germany's DAX 40 rose 0.87% and France's CAC 40 fell 0.58% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with India's BSE Sensex rising 0.37%.
Economics
<ul>
<li>The S&amp;P Global services PMI was revised lower to 50.8 in April 2025 compared to a preliminary reading of 51.4.</li>
<li>The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45192437/how-to-earn-500-a-month-from-williams-companies-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Williams Companies Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Intraday Update

Markets

Trading Ideas

BCRX

GPUS

IART

PTCT

TGTX

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday.
Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/NSSC/earnings">first-quarter financial results</a>.
NAPCO Security Techs reported quarterly earnings of 28 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $43.96 million which beat the analyst consensus estimate of $43.14 million.
Napco Security Technologies shares jumped 9.6% to $26.06 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares jumped 25% to $61.66 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) gained 12.2% to $10.02 after the company reported a first-quarter sales beat.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) gained 10% to $11.44.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) gained 9.2% to $3.67.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) climbed 8.7% to $124.64.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) rose 7.7% to $22.84.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) shares gained 7% to $16.09.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) gained 6.2% to $18.13.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) climbed 5.4% to $4.2050. The company posted upbeat quarterly earnings on Friday.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) gained 5.2% to $54.69. Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises from Hold to Buy and raised the price target from $54 to $67.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) shares rose 4.9% to $17.90.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

News

Movers

NSSC

NUTX

PONY

ULCC

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday

WIIM

BioCryst Pharmaceuticals shares are trading higher after the company reported a Q1 sales beat.

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 106.2% to $0.95 during Monday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock rose 22.22% to $2.2. The company's market cap stands at $10.8 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 15.63% to $3.78. The company's market cap stands at $30.5 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares rose 14.89% to $10.26. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock moved upwards by 14.88% to $1.16. The company's market cap stands at $11.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 11.31% to $6.79. The market value of their outstanding shares is at $139.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock declined by 89.9% to $1.7 during Monday's pre-market session. The company's market cap stands at $104.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.53% to $0.59. The market value of their outstanding shares is at $6.7 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 21.32% to $0.4. The market value of their outstanding shares is at $9.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 16.21% to $1.5. The market value of their outstanding shares is at $19.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock decreased by 14.39% to $1.25. The market value of their outstanding shares is at $17.9 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.09% to $0.43. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

APVO

IBIO

MODV

NCNA

PLRX

QNRX

RNAZ

12 Health Care Stocks Moving In Monday's Pre-Market Session

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly sales of $145.53 million which beat the analyst consensus estimate of $126.87 million by 14.71 percent. This is a 56.89 percent increase over sales of $92.76 million the same period last year.

Earnings Beats

BioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

BioCryst Grants 48,000 RSUs To New Hires As Employment Inducement Under Nasdaq Rule

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Overweight rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and maintains $11 price target.

Reiteration

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $15 price target.

Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target

Management

BioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025

Citizens Capital Markets analyst Jonathan Wolleben reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Market Outperform and maintains $18 price target.

Citizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $10 to $11.

RBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $11

HC Wainwright &amp; Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $30 price target.

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

On Monday, BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) released results from an interim analysis of the ongoing APeX-P trial.
The study centered on an oral granule formulation of once-daily Orladeyo (berotralstat) in pediatric patients. The patients have hereditary angioedema (HAE) <a href="https://www.benzinga.com/pressreleases/25/02/g43907577/biocryst-announces-positive-results-from-apex-p-trial-for-orladeyo-berotralstat-in-pediatric-patie" target="_blank" rel="noreferrer noopener">aged 2 to 12 years</a>.
<ul>
<li>ORLADEYO was safe and well tolerated in APeX-P, with no new safety signals identified. Adverse events (AEs) were similar across all ages and weights.</li>
<li>ORLADEYO resulted in early and sustained reductions in monthly attack rates. After one month of taking ORLADEYO, the median and mean monthly attack rates dropped to 0 and 0.5, respectively. The median monthly attack rate remained at 0 through month 12, and the mean monthly attack rate at month 12 was 0.3.</li>
</ul>
The company also announced new real-world evidence with Orladeyo showing statistically significant HAE attack rate reductions experienced by patients with HAE with C1-INH deficiency (HAE Type I/II) and normal C1-INH levels and function (HAE-nl-C1-INH).
The company plans to submit an FDA marketing application this year.
Concurrently, BioCryst reported fourth-quarter sales of $131.53 million, up 41% year over year, beating the consensus of $130.15 million.
The company reported an adjusted loss of 13 cents per share, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 6 cents per share</a>.
Orladeyo net revenue increased 36.6% to $124.2 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43908737/biocryst-reports-fourth-quarter-and-full-year-2024-financial-results-and-upcoming-key-milestones" rel="noreferrer noopener">and 34% to $437.7 million</a>.
BioCryst expects 2025 sales of $560 million—$575 million, compared to the prior guidance of $540 million—$560 million and the consensus of $545.31 million.
The company increased its 2025 outlook for Orladeyo revenue to between $535 million and $550 million, from $515 million to $535 million.
The company expects to approach quarterly positive EPS and cash flow in the second half of 2025 and to be profitable on an EPS basis, with positive cash flow, for the full year 2026.
Price Action: BCRX stock is down 11.4% at $8.16 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43911341/owens-corning-reports-robust-q4-performance-forecasts-mid-20-revenue-growth-for-q1-2025" target="_blank" rel="noreferrer noopener">Owens Corning Q4 Earnings: Sales Jump 23%, EPS Beats Estimates, Forecasts Mid 20% Revenue Growth For Q1</a></li>
</ul>
Image: Shutterstock

Biotech

Guidance

Health Care

General

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

BioCryst Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Financial Outlook for 2025
Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million (previously $515 million to $535 million). The company now expects full year 2025 total revenue (including RAPIVAB (peramivir injection)) will be between $560 million and $575 million (previously $540 million to $560 million).
The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million (not including stock-based compensation). The revenue related operating expense increases are captured at the higher end of this range.

BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515M-$535M

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.06) by 116.67 percent. This is a 53.57 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $131.53 million which beat the analyst consensus estimate of $130.15 million by 1.07 percent. This is a 40.83 percent increase over sales of $93.40 million the same period last year.

BioCryst Pharma Q4 2024 Adj EPS $(0.13) Misses $(0.06) Estimate, Sales $131.53M Beat $130.15M Estimate

Press Releases

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst to Present at Upcoming Investor Conferences

BioCryst Appoints Steve Frank to Board of Directors

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

Comments

BioCryst Pharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO